Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating microRNAs and Their Role in Multiple Myeloma.
Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM. Federico C, et al. Among authors: cancelli v. Noncoding RNA. 2019 May 2;5(2):37. doi: 10.3390/ncrna5020037. Noncoding RNA. 2019. PMID: 31052608 Free PMC article. Review.
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M, Giustini V, Facchetti GV, Roccaro AM, Ferrari S, Peli A, Bottelli C, Cattaneo C, Crippa C, Micilotta M, Frittoli B, Grazioli L, Rossi G, Tucci A. Belotti A, et al. Among authors: cancelli v. Cancer Med. 2021 Sep;10(17):5859-5865. doi: 10.1002/cam4.4136. Epub 2021 Jul 15. Cancer Med. 2021. PMID: 34263564 Free PMC article.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, Bottelli C, Cattaneo C, Tucci A, De La Fuente Barrigon C, Rossi G. Belotti A, et al. Among authors: cancelli v. Am J Hematol. 2020 Jul;95(7):759-765. doi: 10.1002/ajh.25797. Epub 2020 Apr 23. Am J Hematol. 2020. PMID: 32242970 Free article. Clinical Trial.
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G. Malagola M, et al. Among authors: cancelli v. Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715369 Free PMC article.
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G. Cattaneo C, et al. Among authors: cancelli v. Cancer. 2020 Dec 1;126(23):5069-5076. doi: 10.1002/cncr.33160. Epub 2020 Sep 10. Cancer. 2020. PMID: 32910456 Free article.
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A, Chiorini JA, Su HC, Cohen JI, Burbelo PD, Rossi G, Notarangelo LD. Cattaneo C, et al. Among authors: cancelli v. Blood Cancer J. 2021 Sep 14;11(9):151. doi: 10.1038/s41408-021-00546-9. Blood Cancer J. 2021. PMID: 34521813 Free PMC article.
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.
Polverelli N, Malagola M, Turra A, Skert C, Perucca S, Chiarini M, Cattina F, Rambaldi B, Cancelli V, Morello E, Schieppati F, Bernardi S, Zanaglio C, Sottini A, Giustini V, Imberti L, Montanelli A, Russo D. Polverelli N, et al. Among authors: cancelli v. Leuk Lymphoma. 2018 Nov;59(11):2700-2705. doi: 10.1080/10428194.2018.1439584. Epub 2018 Mar 12. Leuk Lymphoma. 2018. PMID: 29527964 Clinical Trial. No abstract available.
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation.
Skert C, Perucca S, Chiarini M, Giustini V, Sottini A, Ghidini C, Martellos S, Cattina F, Rambaldi B, Cancelli V, Malagola M, Turra A, Polverelli N, Bernardi S, Imberti L, Russo D. Skert C, et al. Among authors: cancelli v. PLoS One. 2017 Apr 11;12(4):e0175337. doi: 10.1371/journal.pone.0175337. eCollection 2017. PLoS One. 2017. PMID: 28399164 Free PMC article.
Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.
Malagola M, Skert C, Ruggeri G, Turra A, Ribolla R, Cancelli V, Cattina F, Alghisi E, Bernardi S, Perucca S, Di Palma A, Borlenghi E, Pagani C, Rossi G, Caimi L, Russo D. Malagola M, et al. Among authors: cancelli v. Biomed Res Int. 2014;2014:123079. doi: 10.1155/2014/123079. Epub 2014 Aug 17. Biomed Res Int. 2014. PMID: 25202702 Free PMC article.
32 results